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Abstract
Down’s syndrome (DS) is a developmental disorder associated with intellectual disability (ID). We have previously shown
that people with DS engage in very low levels of exercise compared to people with ID not due to DS. Many aspects of the
DS phenotype, such as dementia, low activity levels and poor muscle tone, are shared with disorders of mitochondrial
origin, and mitochondrial dysfunction has been demonstrated in cultured DS tissue. We undertook a phosphorus magnetic
resonance spectroscopy (31P-MRS) study in the quadriceps muscle of 14 people with DS and 11 non-DS ID controls to
investigate the post-exercise resynthesis kinetics of phosphocreatine (PCr), which relies on mitochondrial respiratory
function and yields a measure of muscle mitochondrial function in vivo. We found that the PCr recovery rate constant was
significantly decreased in adults with DS compared to non-DS ID controls (1.760.1 min21 vs 2.160.1 min21 respectively)
who were matched for physical activity levels, indicating that muscle mitochondrial function in vivo is impaired in DS. This is
the first study to investigate mitochondrial function in vivo in DS using 31P-MRS. Our study is consistent with previous
in vitro studies, supporting a theory of a global mitochondrial defect in DS.
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Introduction
Down’s syndrome (DS) is a developmental disorder associated
with triplication of chromosome 21, and affects 1 in 700–1000 live
births [1,2]. The clinical phenotype in DS is variable and multi-
faceted and includes specific physical characteristics and an
increased risk for developing sensory deficits, congenital heart
defects, early onset Alzheimer’s disease (AD), and hypothyroidism
[3]. DS is also associated with obesity and reduced exercise
capacity [4]. We have recently reported reduced physical activity
levels in DS compared to people with intellectual disability (ID)
not due to DS, with the older people with DS being less active than
their younger counterparts [5]. As this use of an ID control group
eliminates a number of general (social and environmental) factors
that might explain this observation, we postulated an underlying
age-related pathophysiology which limits activity in people with
DS, an obvious candidate for which is mitochondrial dysfunction
[5].
Mitochondrial generation of adenosine triphosphate (ATP) is
fundamental to cellular energy turnover, and defects of mitochon-
drial function manifest in a variety of ways in specific clinical
syndromes and in chronic diseases. In general defective mito-
chondrial function in vivo results in limited capacity for ATP
synthesis, and may be associated with increased intracellular levels
of toxic reactive oxygen species (ROS). In vitro studies in DS have
demonstrated mitochondrial abnormalities including mtDNA
mutations [6], global dysregulation of genes associated with
mitochondrial function in the foetus [7], and mitochondrial
enzyme deficiency [8]. However, we are aware of no studies that
have assessed mitochondrial function in vivo in DS. We therefore
undertook a study of DS mitochondrial function in vivo in skeletal
muscle using 31P magnetic resonance spectroscopy (31P-MRS),
which offers a non-invasive method for measuring mitochondrial
function in vivo by analysing the post-exercise recovery kinetics of
phosphocreatine (PCr), a process which relies on mitochondrial
production of ATP [9]. We postulated that participants with DS
would demonstrate a slowed recovery of PCr, indicating a defect
of mitochondrial function in vivo, compared to control participants
with similar levels of ID but not due to DS.
Methods
Ethics Statement
Ethical approval for the study was granted by the Cambridge-
shire 3 Research Ethics Committee and all studies were conducted
in accordance with the principles of the Declaration of Helsinki.
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Only participants judged to have the capacity to consent in
accordance with the Mental Capacity Act (2005) were recruited.
Written consent was obtained from all participants.
Recruitment, Screening and Familiarisation
Participants with ID not due to DS were deliberately chosen as
controls for the DS group in an attempt to match for level of
intellectual disability, environmental factors and fitness levels.
Participants were recruited from a database of participants in a
previous study [5] and were initially selected to match as far as
possible age, gender, BMI and physical activity levels between
groups. We scanned 29 individuals, but after detailed consider-
ation when matching activity levels of the two groups, selected for
analysis 14 DS and 11 ID participants. Inclusion criteria were:
mild to moderate ID; known to ID services; aged $12 y; able to
walk unaided; and able to understand protocol instructions.
Exclusion criteria were: smoking; autism spectrum disorder;
diabetes mellitus, cardiovascular disease; medication known to
effect energy metabolism; and standard magnet contraindications.
Prior to inclusion, participants underwent a preliminary screening
at their home residence to determine whether they would be able
to understand and complete the study protocol, and to assess their
capacity to consent. Two weeks prior to the experimental
measurements participants were shown a video and underwent
at least two familiarisation sessions at their home residence to
ensure they were comfortable with the in-scanner exercise
protocol. All participants underwent at least four separate practice
trials.
Measurements of Height, Weight, and Body Fat
Weight was measured to the nearest 0.1 kg with the participant
dressed in lightweight clothing and without shoes, using a
calibrated electronic scale (Seca 813, Seca Ltd, UK). Height was
measured by the stretch stature method to the nearest 0.5 cm
using a portable stadiometer (Seca Leicester Height Measure,
Invicta Plastics, UK). Percentage body fat was assessed by
bioelectrical impedance using a TBF2521 analyser (Tanita Corp.,
Japan) in accordance with the manufacturer’s instructions.
Measurement of Leg Strength
Two weeks prior to the experimental measurements isometric
leg strength was measured at the participants’ home residence
using a portable back and leg dynamometer (Takei, model T.K.K.
5162, Japan) according to a protocol [10] which has been
validated in both adolescents and adults [10,11].
Assessment of Total Physical Activity
Habitual physical activity was assessed using an Actigraph
GT1M accelerometer (Actigraph LLC, Pensacola, FL, USA) for
seven consecutive days. Accelerometers have been used previously
to assess physical activity in a number of studies in DS [12–14].
The total physical activity measure was used as a measure of
habitual physical activity in these participants and not used to
make inferences on energy expenditure [14]. These participants
formed part of a previous report on activity in these cohorts and
the methodology and analysis were as previously described in that
study [5].
31P-MRS Measurement of Post-exercise PCr Recovery
Kinetics
31P-MRS data were acquired on a Siemens MAGNETOM 3T
Verio scanner. Participants were asked to arrive having refrained
from strenuous exercise for at least 24 h and having abstained
from alcohol, caffeine, and food for the preceding 24 h, 6 h, and
2 h respectively. The volunteers were placed supine and a 9 cm
diameter surface coil attached to the right quadriceps (1/3 distal).
An MR-compatible weight was attached to the right ankle that
was proportional to their previously-determined leg strength, such
that the PCr concentration after exercise was targeted to fall by
20–30% of basal levels, thereby avoiding any significant lowering
of pH which is known to complicate interpretation of PCr
recovery kinetics. The exercise paradigm consisted of 1 min rest,
1 min knee extensions (0.5 Hz), then 4 min rest. This was then
repeated to permit two measurements of post-exercise PCr
recovery, results from the analysis of which were averaged.
Spectra were acquired with a TR of 2s and as previously described
[15]. The PCr recovery rate constant, k, was found using a two
parameter monoexponential fit to the equation: PCr(t) = PCrini-
tial+(PCrend – PCrinitial)(1-exp(-k.t)), where t is the time from the
start of recovery, PCrinitial and PCrend are the PCr content at the
initial and end of recovery phases respectively. MATLAB software
(The MathWorks, Natick, MA, USA) was used to calculate PCrend
from the mean end-recovery PCr values and then to obtain k and
PCrinitial by the Levenberg Marquardt fitting algorithm. All
spectra were analysed in jMRUI [16] and fitted using the
AMARES [17] algorithm with prior knowledge. The intracellular
pH was determined from the chemical shift of inorganic phosphate
relative to PCr. A fully relaxed spectrum with 8 averages was also
obtained for the calculation of metabolite ratios and concentra-
tions. The conventional assumption was made that the intracel-
lular concentration of ATP was 8.2 mM, and the free concentra-
tion of adenosine diphosphate (ADP) was calculated using
established methods [18] with the conventional assumption (in
the absence of any reported data in DS) of total creati-
ne = 42.5 mM. The signal-to-noise ratio (SNR) of the PCr
recovery sequence was defined as the (mean signal)/SD of the
recovered PCr values (20 points, TR=2s). High subcutaneous
adipose tissue thicknesses can result in a low SNR and uncertainty
in the accuracy of the PCr recovery rate constant, and hence a cut
off value of SNR ,35 was chosen for exclusion of k values.
Statistics
Statistical analysis was performed in IBM SPSS Statistics 21
(IBM Inc., Armonk, NY, USA), with significance set at p,0.05. A
two-tailed independent samples t-test was performed to detect
significant differences between groups.
Results
Participants with ID not due to DS and participants with DS
were matched for age, gender, BMI and physical activity levels,
and were found to have similar percentage body fat (Table 1).
However, the DS were significantly shorter than the ID controls
(p = 0.001). No significant correlation of total physical activity with
age was found in either group, or altogether.
Four participants with DS were eliminated from the calculation
of k due to not meeting the SNR requirements described in the
Methods section, and hence the 31P-MRS and accelerometry
results in Table 2 represent the DS group with n= 10. Post-
exercise PCr recovery was significantly slowed in the DS group
compared with ID (p = 0.039, Figure 1). Neither the resting nor
end-exercise intracellular pH (pHi) differed significantly between
those with DS and those with ID without DS (Table 2), and end-
exercise pHi was not significantly lower than resting pHi in either
group. No differences in resting metabolite concentrations nor
their ratios were found between the groups (Table 2). There was
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no significant correlation between total physical activity and the
PCr recovery rate constant, k in either group, or altogether.
Discussion
We found significantly slower post-exercise PCr recovery in
skeletal muscle of the participants with DS compared with the
non-DS ID control participants. Post-exercise PCr recovery,
conveniently measured as the recovery rate constant, which was
16% lower in the DS participants, is a measure of mitochondrial
function in vivo which integrates the contributions of muscle
mitochondrial numbers, the mitochondrial content of enzymes,
transporters and respiratory chain complexes, the activity of
relevant cytosolic enzymes, and the whole-body cardiorespiratory
physiology affecting substrate and oxygen supply to active muscle
[19]. In exercise of the kind used here the exercising muscle mass
is very small (compared e.g. to bicycle ergometry [20]), and
cardiovascular limitations to this measure are normally negligible.
Our participants with DS had no clinical evidence of cardiovas-
cular or pulmonary disease, and therefore no reason to suppose
that the defect we identified lies ‘upstream’ of the mitochondrion.
The likeliest explanation is either a lower mitochondrial content,
or a defect in intrinsic mitochondrial metabolism.
There are various lines of in vitro evidence to support, or at least
parallel, our findings of mitochondrial dysfunction in vivo in DS.
Previous in vitro studies in DS have shown mtDNA mutations or
mitochondrial dysfunction in brain [6,21–23] and dysregulation of
genes associated with mitochondrial function in foetal heart tissue
[7]. More specifically lower mRNA levels of complex I and
decreased protein levels in complex I subunits [21] as well as
decreased levels of complex V [24] have been identified in the
brains of people with DS. Levels of mitochondrial enzymes in
platelets, including cytochrome oxidase (COX), have been shown
to be significantly lower in people with DS compared with controls
[8]. There is also evidence of compensation for mitochondrial
inefficiency, including a 25% increase in mitochondrial mass of
fibroblasts in people with DS [25]. A recent study by Helguera
et.al. [26] has shown that mitochondria move more slowly in DS
neurons compared with controls, although there were higher
numbers of moving mitochondria in DS at any given time that
may be a compensatory mechanism. Collectively the results from
these studies suggest a systemic long standing dysfunction of
mitochondria in DS. To our knowledge, there have been no such
studies in DS investigating skeletal muscle, which for practical
reasons is the only tissue in which mitochondrial function in vivo
(i.e. the capacity for mitochondrial ATP synthesis) can be
quantified non-invasively [19]. The results of our in vivo study in
skeletal muscle support this theory of a global mitochondrial
defect.
We have previously shown that people with DS have highly
sedentary lifestyles compared to their non-DS ID peers [5].
Similarly low levels of habitual physical activity have recently been
reported in people with mitochondrial disease [27]. In addition,
the authors of that study found a high prevalence of obesity, and a
moderate negative correlation between steps walked per day and
disease severity. We suggest that low levels of activity, the reduced
Table 1. Characteristics of the participants with Down’s
syndrome (DS) and those with a non Down’s syndrome
related intellectual disability (ID).
DS (n=14) ID (n =11) p-value
Age (yrs) 32.7 (2.2) 29.8 (2.7) 0.410
Gender 8 M, 6 F 5 M, 6F 0.580
Weight (kg) 72.2 (3.2) 80.0 (4.9) 0.175
Height (m) 1.55 (0.03) 1.72 (0.04) 0.001
BMI (kg/m2) 30.4 (1.7) 26.9 (1.1) 0.100
Percentage body fat (%) 27.5 (2.7) 27.5 (3.1) 0.991
Data presented are mean (SEM).
M, Male; F, Female; BMI, body mass index.
doi:10.1371/journal.pone.0084031.t001
Table 2. Accelerometry and 31P-MRS measurements for the participants with Down’s syndrome (DS) and those with a non Down’s
syndrome related intellectual disability (ID).
Category Subcategory DS (n=10) ID (n =11) p-value
Accelerometry Total physical activity (counts/min) 542.5 (25.3) 611.6 (35.1) 0.133
31P-MRS Exercise weight (kg) 2.03 (0.10) 2.77 (0.29) 0.031
k (min21) 1.72 (0.10) 2.06 (0.12) 0.039
Resting Pi:PCr 0.086 (0.005) 0.096 (0.006) 0.216
Resting PDE:PCr 0.123 (0.011) 0.115 (0.007) 0.567
Resting Pi:PDE 0.73 (0.06) 0.86 (0.07) 0.213
Resting [Pi] (mM) 2.85 (0.16) 2.96 (0.17) 0.633
Resting [PDE] (mM) 4.07 (0.35) 3.58 (0.22) 0.244
Resting [PCr] (mM) 33.4 (0.7) 31.2 (0.9) 0.073
End exercise [PCr] (mM) 26.5 (1.5) 24.3 (0.9) 0.211
Resting [ADP] (mM) 14.7 (1.8) 20.2 (2.3) 0.078
End exercise [ADP] (mM) 36.8 (4.9) 45.2 (4.6) 0.227
Resting pHi 7.017 (0.015) 7.036 (0.007) 0.281
End exercise pHi 7.061 (0.010) 7.068 (0.009) 0.648
Data presented are mean (SEM).
k, PCr recovery rate constant; [Pi], concentration of inorganic phosphate; [PCr], concentration of phosphocreatine; [PDE], concentration of phosphodiester; [ADP],
concentration of adenosine diphosphate; pHi, intracellular pH.
doi:10.1371/journal.pone.0084031.t002
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capacity for exercise [4] and high rates of obesity [28] in DS could
be accounted for in part by reduced mitochondrial ability of
skeletal muscle to generate ATP.
However, any cross-sectional study relating habitual activity to
muscle energetics (in this case, muscle mitochondrial capacity)
must address the issue of causal direction; whilst mitochondrial
dysfunction in vivo can certainly contribute to reduced habitual
activity, it is also possible that reduced activity may lead to
impaired muscle mitochondrial function. In the present study we
have tried to address this by matching the DS and non-DS ID
groups for physical activity. The data does not exist to say how
much a ‘primary’ reduction in habitual activity would be necessary
to yield the 16% defect we observed in mitochondrial function
in vivo in DS compared to non-DS ID, nor conversely how much a
primary mitochondrial defect (in mitochondrial numbers or
intrinsic mitochondrial activity) of this size would be expected,
on its own, to limit activity. We do know that the ‘slope’ of the
relationship between these two measures is steep, in the sense that
symptomatic primary mitochondrial myopathy is associated with
on average a 40–50% defect in skeletal muscle mitochondrial
capacity as measured by 31P-MRS [29]. The defect we have
identified here is therefore likely to be functionally significant, even
if we cannot be sure whether it is cause or effect (or both).
Precocious ageing and Alzheimer’s disease (AD) are strikingly
common in DS, with almost 100% of people with DS eventually
developing the neuropathology of AD [30], which is likely to be
linked to the overexpression of the amyloid precursor protein gene
(APP) resulting in a lifelong excess of beta-amyloid (Ab). The role
of mitochondrial dysfunction in neurodegenerative diseases is well-
established [31]. Ab has been shown to be imported into
mitochondria where it inhibits function [32,33], and data indicate
that mitochondrial dysfunction contributes to the development of
DSAD [34]. Ab deposits have been seen in non-brain tissue of
people with AD, DS and in normal ageing [35]. Further, transfer
of the bAPP gene into cultured normal human muscle leads to
decreased mitochondrial enzyme activity and structural abnor-
malities [36]. This demonstrates that mitochondrial interaction
with Ab is not limited to brain, and suggests, further, that
mitochondrial dysfunction quantified in muscle in vivo, as in the
current study, may provide insight into Ab and mitochondria in
Figure 1. 31P-MRS measures of mitochondrial function. (A) Representative single spectra (NA= 1) at rest (upper) and near end exercise (lower),
with 2 Hz line broadening applied for illustrative purposes. (B) Corresponding PCr timecourse to the spectra in A, which illustrates the typical [PCr]
end-exercise depletion in this study. The SNR of this timecourse was 46, significantly below average. The black line represents the monoexponential
fit to both PCr recoveries. The recovery time constant, k, was 1.87 min21 and 1.83 min21 for recovery from exercise bouts 1 and 2 respectively. (C)
Mean fractional PCr recovery curves for physical activity matched ID (grey squares; n = 11) and DS (black circles; n = 10). Five spectra were averaged to
give a time resolution of 10 seconds for clarity in this figure. The monoexponential fit using the mean recovery rate constant is shown for ID (grey
line) and DS (black line). (D) Recovery rate constant (k) for matched physical activity groups of ID (white bars; n = 11) and for DS (black bars; n = 10). In
C–D, data are mean +/2 SEM.
doi:10.1371/journal.pone.0084031.g001
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brain. Mitochondrial dysfunction and mutations of mtDNA are a
major hallmark of human ageing [37], suggesting that mitochon-
dria may underlie the precocious biological ageing that is
characteristic of DS. In the current study, there was no significant
correlation with age in the DS group (p=0.165, data not shown)
although the eldest person in the group was only 44 y.
Low activity levels in DS are associated with reduced life
expectancy, irrespective of heart disease [38]. Increasing mobility
of people with DS should therefore improve well-being as well as
mortality. Furthermore, high levels of exercise in people over 65 y
in the general population has been shown to be protective against
cognitive decline [39], adding further support to the notion that
reduced habitual activity in DS may impact on the rate and
severity of dementia, although mitochondrial dysfunction may
underlie both these aspects of the phenotype. Understanding
reasons for reduced habitual activity in DS, including the role of
mitochondrial dysfunction and accumulation of mtDNA muta-
tions, may be key to a number of health issues associated with the
syndrome.
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